Ore; she has lectured at symposia sponsored by Allergan; she is PI or collaborator in clinical trials sponsored by Alder, electroCore, Eli-Lilly and Teva. She has received grants from the European Commission, the Italian Ministry of Health and also the Italian Ministry of UniversityReferences Scher AI, Buse DC, Fanning KM, Kelly AM, Franznick DA, Adams AM, Lipton RB. Comorbid discomfort and 6-Iodoacetamidofluorescein Data Sheet migraine chronicity: The Chronic Migraine Epidemiology and Outcomes Study. Neurology. 2017 Aug 1;89(5):461468. 1. Silberstein SD, Diamond S, Loder E, et al. Prevalence of migraine sufferers who’re candidates for preventive therapy: outcomes in the American migraine study (AMPP) study. Headache 2005; 45: 770771. Tassorelli C, Jensen R, Allena M, De Icco R, Katsarava Z, Miguel Lainez J, Leston JA, Fadic R, Spadafora S, Pagani M, Nappi G; COMOESTASThe Journal of Headache and Discomfort 2017, 18(Suppl 1):Page 18 ofConsortium. The added value of an electronic monitoring and alerting technique inside the management of medication-overuse headache: A controlled multicentre study. Cephalalgia. 2016 [Epub ahead of print]S52 Comorbidities in principal headaches Antonio Carolei1,two, Cindy Tiseo1, Diana Degan1 1 Institute of Neurology, Department of Applied Clinical Sciences and Biotechnology, University of L’Aquila, through Vetoio, 67100 L’Aquila, Italy; two Division of Neurology and Stroke Unit, Avezzano Hospital, 67051, Avezzano, Italy Correspondence: Antonio Carolei ([email protected]) The Journal of Headache and Discomfort 2017, 18(Suppl 1):S52 Based on the International Classification of Headache Disorders, 3rd edition (beta version) [1], key headaches are classified as “migraine”, “tension-type headache”, “trigeminal autonomic cephalalgia”, and “other key headache disorders”. To date, the majority of clinical studies regarding key headaches and their comorbidities are focused on migraine. Comorbidities of migraine may involve neurological and psychiatric circumstances, as mood issues (depression, mania, anxiousness, panic attacks), epilepsy, necessary tremor, stroke, along with the presence of white matter abnormalities [2]. Particularly, a complex and bidirectional relation among migraine and stroke has been described, including migraine as a danger aspect for cerebral ischemia, migraine brought on by cerebral ischemia, migraine mimicking cerebral ischemia, migraine and cerebral ischemia sharing a prevalent lead to, and migraine connected with subclinical vascular brain lesions [2]. A recent meta-analysis pointed out that migraine is related with increased ischemic stroke threat [3], and in accordance with a Calcium ionophore I medchemexpress systematic overview and meta-analysis [4] the risk of hemorrhagic stroke in migraineurs is improved with respect to non-migraineurs. In addition to, the threat of transient ischemic attack appears to become enhanced in migraineurs, even though this problem has not been extensively investigated [5]. A current systematic critique and meta-analysis also describes an increased threat of myocardial infarction and angina in migraineurs compared to nonmigraineurs [6]. Regarding the association between migraine and vascular danger factors (arterial hypertension, diabetes mellitus, dyslipidemia, obesity, alcohol consumption, loved ones history of cardiovascular illness), a current critique [7] showed no strong evidence of an enhanced burden of traditional vascular risk factors in migraineurs, with the only exceptions of dyslipidemia and cigarette smoking, even though a systematic critique and meta-analysis regarding migraine and bod.
